Milestone Pharmaceuticals (MIST) AI Stock Analysis

• Market Cap: $56.56M
• Dividend Yield: N/A
• Average Volume (3M): 3.82M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.60
• Revenue Growth: -100.00%
• EPS Growth: 51.19%
• Country: US
• Employees: 33
• Sector: Healthcare
• Sector Strength: 64
• Industry: Biotechnology
• EPS (TTM): -0.72
• Shares Outstanding: 53,353,985
• 10 Day Avg. Volume: 1,409,901
• 30 Day Avg. Volume: 3,823,430
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 101.37
• Price to Cash Flow (P/CF): -3.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $7.50
• Price Target Upside: 546.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

Milestone Pharmaceuticals' overall stock score reflects substantial financial difficulties, including no revenue and negative cash flows. However, the upcoming launch of CARDAMYST provides a potential turnaround opportunity, which is a significant positive factor. Technical indicators suggest a bearish trend, and valuation metrics highlight the lack of earnings and dividends, indicating a speculative investment.

Positive Factors

Financial Stability

Milestone has a cash runway expected to last into mid-2026, providing financial stability until the anticipated launch.

Market Opportunity

The PSVT market remains significantly underserved, presenting a notable opportunity for CARDAMYST as a first-line, in-pocket treatment for acute PSVT episodes.

Potential Approval

If approved, CARDAMYST would be the first self-administered, rapid-acting therapy designed to terminate PSVT episodes outside a medical setting, offering patients a novel approach to managing their condition without the need for emergency intervention.

Negative Factors

Regulatory Challenges

The FDA issued a Complete Response Letter for CARDAMYST due to Chemistry, Manufacturing, and Controls issues, delaying approval.

Regulatory Delays

The launch of CARDAMYST has been delayed due to a Complete Response Letter from the FDA, pushing the potential launch timeline by approximately one year.

Stock Downgrade

The stock rating for MIST was downgraded to Hold due to uncertainty surrounding the regulatory and commercial timing of etripamil.

Milestone Pharmaceuticals Business Overview & Revenue Model

Company Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

How the Company Makes Money

Milestone Pharmaceuticals generates revenue through the development and commercialization of its pharmaceutical products, primarily etripamil. The company aims to secure regulatory approvals and bring its products to market, targeting healthcare providers and institutions as its primary customers. Revenue streams are expected from product sales, potential partnerships, and licensing agreements with larger pharmaceutical companies that may include upfront payments, milestones, and royalties. Additionally, strategic collaborations and partnerships can enhance its market reach and provide funding to support further research and development efforts, contributing to its overall earnings.

Milestone Pharmaceuticals Financial Statement Overview

Summary

Milestone Pharmaceuticals faces significant financial challenges, with no revenue in the latest period, high leverage, and negative cash flows. The company must address its revenue generation and operational efficiency to improve financial health. Despite these challenges, liquidity remains relatively strong, providing a short-term buffer.

Income Statement

The income statement reveals that Milestone Pharmaceuticals is struggling with revenue generation, recording zero revenue for the most recent year and significant net losses consistently. Gross and net profit margins are negative, reflecting ongoing operational challenges in achieving profitability.

Balance Sheet

The balance sheet indicates high leverage with a debt-to-equity ratio increasing over time due to declining equity. The equity ratio is low, and the company's liabilities are a significant portion of its assets, raising concerns about financial stability. However, cash reserves are relatively robust compared to liabilities, providing some liquidity cushion.

Cash Flow

Cash flow from operations is negative, and free cash flow remains substantially negative, indicating ongoing cash burn. While there is some improvement in financing cash flows, the reliance on external financing highlights the need for sustainable cash generation from operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	1.00M	5.00M	15.00M	0.00
	Gross Profit
0.00	1.00M	4.52M	15.00M	-376.00K
	EBIT
-42.10M	-61.10M	-59.64M	-43.07M	-50.71M
	EBITDA
-42.10M	-56.84M	-58.36M	-42.98M	-50.71M
	Net Income Common Stockholders
0.00	-59.69M	-57.13M	-42.63M	-49.97M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
69.69M	66.00M	64.58M	114.14M	142.31M
	Total Assets
75.50M	75.23M	74.48M	119.85M	149.97M
	Total Debt
54.80M	51.77M	2.49M	698.00K	941.00K
	Net Debt
29.48M	38.02M	-5.14M	-113.44M	-71.37M
	Total Liabilities
62.35M	58.45M	8.13M	7.25M	6.86M
	Stockholders Equity
13.15M	16.77M	66.35M	112.60M	143.12M
Cash Flow		Free Cash Flow
-28.85M	-46.54M	-52.74M	-33.22M	-50.73M
	Operating Cash Flow
-28.85M	-46.42M	-52.47M	-33.22M	-50.73M
	Investing Cash Flow
8.28M	4.76M	-57.12M	70.00M	-70.00M
	Financing Cash Flow
32.12M	47.79M	3.09M	5.05M	73.22M

Milestone Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.16
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MIST, the sentiment is Neutral. The current price of 1.16 is above the 20-day moving average (MA) of 0.96, below the 50-day MA of 1.58, and below the 200-day MA of 1.65, indicating a neutral trend. The MACD of -0.18 indicates Negative momentum. The RSI at 49.79 is Neutral, neither overbought nor oversold. The STOCH value of 93.87 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MIST.

Milestone Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CTMX	64 Neutral	$58.96M	1.86	-58.97%	―	36.45%	―
Sector *	51 Neutral	$5.20B	3.26	-40.34%	2.93%	17.68%	1.94%
ATNM	40 Underperform	$43.05M	―	-110.63%	―	-100.00%	30.65%
IPSC	39 Underperform	$46.46M	―	-73.14%	―	194.85%	29.50%
MIST	39 Underperform	$56.56M	―	-277.55%	―	-100.00%	51.19%
ANEB	35 Underperform	$39.85M	―	-71.49%	―	―	28.92%

Milestone Pharmaceuticals Corporate Events

Milestone Pharmaceuticals Prepares for CARDAMYST Launch

On February 25, 2025, Milestone Pharmaceuticals announced its preparation for the potential launch of CARDAMYST, a nasal spray containing etripamil, pending FDA approval. The company anticipates a significant impact on its operations with the expected approval and commercial launch in mid-2025, which could extend its patent estate to 2042 and provide a $75 million payment upon approval. This development is seen as transformative for Milestone, potentially reducing healthcare costs and empowering patients by providing a new therapeutic option.